ASRT vs GSK · rev $125.0M vs P/E 13, $103.31B cap
Assertio Therapeutics Inc (ASRT) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Assertio Therapeutics Inc (ASRT) is a drug manufacturers - specialty & generic company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported ASRT revenue for 2024-12-31 was $125.0M. Net income was -$21.6M. Revenue was down 17.8% from 2023-12-31 to 2024-12-31. ASRT currently screens at market cap $151.5M.
GSK does not have a complete income-statement cache yet.
ASRT currently screens at market cap $151.5M. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the ASRT and GSK stock pages for the full models.
Not investment advice.